Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

• Main Authors: Yuan Yuan, Ferdynand J. Kos, Ting-Fang He, Hongwei H. Yin, Mengsha Li, Nicola Hardwick, Kathryn Zurcher, Daniel Schmolze, Peter Lee, Raju K. Pillai, Vincent Chung, Don J. Diamond
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2017-12-01
• Series: OncoImmunology
• Subjects: immunotherapy; mva; p53; pd-1; pembrolizumab; triple negative breast cancer; t cell response; vaccine; vaccinia
• Online Access: http://dx.doi.org/10.1080/2162402X.2017.1363138
• ISSN: 2162-402X

A heavily pretreated patient with triple negative breast cancer distinguished by cutaneous metastases received p53MVA vaccine in combination with pembrolizumab. Her cutaneous metastases regressed and after 2 cycles of therapy, a skin biopsy showed a complete pathological response. Systemic response was confirmed with restaging CT and bone scans. Activation of p53-specific T cell responses and elevation of multiple immune response genes in peripheral blood correlated with the rapid clinical response which lasted for 6 months after the initiation of combined therapy.